Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock - CYCCP STOCK NEWS

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference. Management will present on the Targeted Oncology Panel on March 14, 2022, at 10:00 AM ET in a fireside chat format. Additionally, the company will have a separate presentation on March 17, 2022, from 12:40 PM to 1:10 PM ET. Both sessions will be accessible via registration links, and replays will be available for 90 days. Cyclacel focuses on developing innovative cancer treatments based on cell cycle and transcriptional regulation.

Cyclacel Pharmaceuticals announced its participation in the 2022 BIO CEO & Investor Conference from February 14-17, 2022. The event will include 1-on-1 virtual meetings with senior management and an on-demand presentation available from February 11, 2022. Cyclacel focuses on developing innovative cancer medicines, including fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor. Interested parties can access the presentation on Cyclacel's website for 90 days post-conference.

Cyclacel Pharmaceuticals provided a business update on January 6, 2022, highlighting its achievements in 2021 and objectives for 2022. The company initiated two registration-directed trials for its lead candidate, oral fadraciclib, an oral CDK2/9 inhibitor, aiming to address solid tumors and hematological malignancies. Additionally, they received FDA clearance for a Phase 1/2 study of CYC140, a PLK1 inhibitor. Cyclacel raised $14.5 million in early 2021, ensuring financial stability until early 2023, with key data readouts expected in 2022.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced participation in the Biotech Showcase 2022 Virtual Conference on January 10-12, 2022. CEO Spiro Rombotis will present an overview of the company and engage in virtual meetings. He will also lead a workshop titled “Outsmarting Cancer: Next Generation Therapies” on January 10 at 8:00 AM PT/11:00 AM ET. The conference presentation and archived webcast will be accessible on the company’s website for 90 days after January 3, 2022, enhancing investor insight into Cyclacel's innovative cancer therapies.

Cyclacel Pharmaceuticals reported its Q3 2021 financial results, highlighting ongoing clinical studies for fadraciclib and CYC140. The company is currently enrolling patients in two Phase 1/2 studies for fadraciclib in leukemia and advanced solid tumors. As of September 30, 2021, Cyclacel had $40.2 million in cash, projecting a runway through early 2023. R&D expenses rose to $4.2 million from $1.1 million in Q3 2020, primarily due to increased clinical trial activities. The net loss for the quarter was $5.0 million, up from $2.3 million in the same period last year.

Cyclacel Pharmaceuticals has initiated dosing for the first patient in a multi-cohort Phase 1/2 trial of fadraciclib, a next-generation CDK2/9 inhibitor, targeting patients with leukemias and myelodysplastic syndromes (MDS). This follows the company's recent progress in a solid tumor and lymphoma study. The trial aims to define the recommended Phase 2 dose and will explore fadraciclib both as a single agent and in combination therapies, potentially establishing new treatment options for these patients.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will announce its third quarter financial results and provide a business update on November 10, 2021, at 4:30 p.m. Eastern Time. The company specializes in developing innovative cancer medicines targeting cell cycle and transcriptional regulation. Key programs include fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor. A conference call will be hosted where stakeholders can participate and access details through the company's website.

Cyclacel Pharmaceuticals will participate in three investor conferences in September 2021, highlighting its commitment to engaging with the investment community. The conferences include the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20-22, and the Cantor Fitzgerald Global Healthcare Conference from September 27-30. Cyclacel is focused on developing innovative cancer medicines and will showcase its pipeline during these events.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced the dosing of its first three patients with advanced solid tumors in the Phase 1/2 trial of oral fadraciclib. This trial will assess the drug's efficacy across various cancer types, building on previous positive data. The company is also preparing to initiate the CYC140 study targeting KRAS mutant cancers. As of June 30, 2021, Cyclacel reported $43.6 million in cash, sufficient to fund operations into early 2023. However, the net loss increased to $5.1 million for Q2 2021 from $2.2 million in Q2 2020.